AbbVie Inks Pact with Gedeon Richter to Discover and Develop Novel Targets for Neuropsychiatric Conditions
Shots:
- AbbVie and Gedeon Richter have entered into a new discovery, co-development and licensing agreement to identify novel targets focusing on the treatment of neuropsychiatric conditions
- Both the companies will share preclinical & clinical R&D costs, with Richter receiving $25M upfront as well as development, regulatory & commercialization milestones plus sales-based royalties. AbbVie will hold global commercialization rights excl. EU, Russia, CIS countries & Vietnam
- Additionally, the partnership has also introduced cariprazine (Vraylar/Reagila) and discovered ABBV-932 for treating bipolar depression and anxiety
Ref: AbbVie | Image: AbbVie & Gedeon Richter
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
